Used as a potent inhibitor in targeted cancer therapies, particularly in the development of kinase inhibitors for treating solid tumors. Its structure enables high selectivity and binding affinity to specific mutant forms of epidermal growth factor receptor (EGFR), making it effective against non-small cell lung cancer (NSCLC) with EGFR resistance mutations. The compound demonstrates strong cellular activity and favorable pharmacokinetic properties, supporting its use in oral dosage forms for prolonged treatment regimens. It is primarily employed in clinical and preclinical research as a lead compound for next-generation anticancer agents.